BILLS-117hr6875ih.pdf

6875 IH later than 180 days each of fiscal years 2022 2022 later than 1 year one year FEBRUARY 28 15 years 2022 through 2025

SESSION H. R. 6875 the ‘‘Right Drug Dose

PO 00000 Frm 00007 PO 00000 Frm 00001 PO 00000 Frm 00002 PO 00000 Frm 00017 PO 00000 Frm 00010 PO 00000 Frm 00012

United States the United States of America

AWARD.—In

DSK79L0C42PROD SEC Congress Child Health and Human Development PHARMACOGENOMIC Health and Human Services the National Library of Medicine nome Research Institute Genome Research Institute the Federal Interagency Steering the Federal Food, Drug Adverse Drug Event Prevention tem THE HOUSE OF REPRESENTATIVES U.S.C. Biotechnology Information United the Public Health Service Act the Public Health Service stakeholder Health Resources and Services Administration Adverse Drug Event Prevention of National Institute of Child Health and Human the National Center for Bio- Committee the National Center for Bio- 6 technology Information Institute House of Representa- Institutes of Health the National Human Genome FUNDS.—A tional Library of Medicine Federal Food, Drug the National Center 11 the Centers for Medicare & Medicaid the Department of Health and Human Services the National Center for Biotechnology Informa- APPROPRIATIONS.—To National the FDA Adverse Event Library of Medicine Food and Drugs the Genomic Community Resources Senate the Committee on Energy and Commerce the FDA Adverse Event Reporting System

Eunice Kennedy Shriver Eunice Kennedy SWALWELL EMMER pharmacogenomic test- 4

adverse action plan drug events event testing verse inpatient director national visits electronic health national human awareness child health departments